News

Biohaven says anti-cancer agent cut tumor size with Regeneron’s Libtayo in Phase 1 trial
Biohaven (NYSE:BHVN) shares traded higher on Wednesday after the company said its antibody-drug conjugate BHV-1510 with ...
Barchart on MSN2d
Regeneron Pharmaceuticals Stock: Is Wall Street Bullish or Bearish?
With a market cap of $63.5 billion, Regeneron Pharmaceuticals, Inc. (REGN) is a fully integrated biotechnology company that ...
Healthline2y
All About Libtayo
If you have a certain kind of skin or lung cancer, your doctor may recommend Libtayo to treat your condition. Libtayo is a prescription medication that’s used in adults to treat the following ...
Business Insider2y
ESMO Presentations of Libtayo® (cemiplimab), Fianlimab and Novel Bispecific Antibodies Showcase Expanding Potential of Regeneron's Oncology Pipeline in Multiple Cancers
New and updated investigational data for Libtayo as monotherapy and as a potential backbone of several combination treatments will also be presented at ESMO. In skin cancers, this includes a mini ...
Yahoo Finance2y
Libtayo® (cemiplimab) in Combination with Chemotherapy Receives Positive CHMP Opinion for the Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
Specifically, the CHMP recommended the Libtayo combination be approved in the European Union (EU) for first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC ...
WebMD7mon
How Libtayo Works for Non-Small-Cell Lung Cancer
How Does Libtayo Work for Non-Small-Cell Lung Cancer (NSCLC)? Libtayo is a specific kind of medicine called immunotherapy. Immunotherapies work by helping your body’s own immune system work to ...
Seeking Alpha4mon
Adjuvant Libtayo® (cemiplimab) Significantly Improves Disease-Free Survival (DFS) After Surgery in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) in Phase 3 Trial
“At the first prespecified interim analysis, Libtayo achieved a remarkably high bar in improving disease-free survival in high-risk cutaneous squamous cell carcinoma. With no currently approved ...
Nasdaq2y
Libtayo® (cemiplimab) Approved in Japan for Advanced or Recurrent Cervical Cancer
"With this approval, Libtayo becomes the first single-agent immunotherapy approved in Japan for the treatment of advanced cervical cancer." The MHLW approval is based on positive data from the ...
Reuters2y
Regeneron buys rights to cancer drug Libtayo from Sanofi
June 2 (Reuters) - Regeneron Pharmaceuticals (REGN.O), opens new tab said on Thursday it would buy the global rights to cancer drug Libtayo from French drugmaker Sanofi SA (SASY.PA), opens new tab ...
FOX40 News2y
Libtayo® (cemiplimab-rwlc) in Combination with Chemotherapy Approved by the FDA as First-line Treatment for Advanced Non-small Cell Lung Cancer (NSCLC)
Approval based on superior survival outcomes of Libtayo plus chemotherapy, compared to chemotherapy alone, in a patient population with a wide range of disease characteristics Second advanced ...
FiercePharma2y
Regeneron's Libtayo finally scores Keytruda-matching FDA nod in newly diagnosed lung cancer. Can it catch up?
After weeks of an inspection-related delay, Regeneron has finally won a much-anticipated FDA approval for Libtayo in newly diagnosed non-small cell lung cancer (NSCLC), opening another front to ...
KRON4 News2y
Libtayo® (cemiplimab) in Combination with Chemotherapy Approved by European Commission for the First-line Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
TARRYTOWN, N.Y., March 29, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Commission (EC) approved Libtayo ® (cemiplimab) in combination ...